ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,297.10
-0.21%
Dow Jones
39,869.38
-0.10%
US Dollar vs MXN
16.68975
0.05%
Brent Oil
83.60
0.47%
Bitcoin
66,143.62
1.39%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. USOTC
  6. Genmab A S (PK) (GNMSF)

  7. Genmab A S (PK) (GNMSF) Noticias

GNMSF

Genmab A S (PK) (GNMSF)

Genmab A S (PK)
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:USOTC:GNMSF
FechaHoraFuenteTítuloSímboloCompañía
08/05/202411:46Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]USOTC:GNMSFGenmab A S (PK)
10/06/202006:34Edgar (US Regulatory)Report of Foreign Issuer (6-k)USOTC:GNMSFGenmab A S (PK)
30/03/202016:16Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)USOTC:GNMSFGenmab A S (PK)
07/02/202007:56Edgar (US Regulatory)Statement of Ownership (sc 13g)USOTC:GNMSFGenmab A S (PK)
14/08/201908:27Edgar (US Regulatory)Unknown (sec Staff)USOTC:GNMSFGenmab A S (PK)
19/07/201905:02Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)USOTC:GNMSFGenmab A S (PK)
18/07/201908:32Edgar (US Regulatory)Securities Registration (ads, Immediate) (f-6ef)USOTC:GNMSFGenmab A S (PK)
18/07/201905:01Edgar (US Regulatory)Notice of Effectiveness (effect)USOTC:GNMSFGenmab A S (PK)
17/07/201918:56Edgar (US Regulatory)Registration of Additional Securities (up to 20%, Foreign Issuer) (f-1mef)USOTC:GNMSFGenmab A S (PK)
17/07/201916:25Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)USOTC:GNMSFGenmab A S (PK)
16/07/201907:55Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)USOTC:GNMSFGenmab A S (PK)
16/07/201907:06Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1/a)USOTC:GNMSFGenmab A S (PK)
15/07/201916:02Edgar (US Regulatory)Post-effective Amendment to a Previously Filed F-6. (f-6 Pos)USOTC:GNMSFGenmab A S (PK)
15/07/201913:38Edgar (US Regulatory)Certification by the Exchange Approving Securities for Listing (cert)USOTC:GNMSFGenmab A S (PK)
12/07/201915:53Edgar (US Regulatory)Securities Registration (section 12(b)) (8-a12b)USOTC:GNMSFGenmab A S (PK)
28/05/201915:29Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1)USOTC:GNMSFGenmab A S (PK)
31/07/201413:50GlobeNewswire Inc.GSK and Genmab Announce Positive Interim Result for Phase III Study of Ofatumumab as Maintenance Therapy for Relapsed CLLUSOTC:GNMSFGenmab A S (PK)
23/07/201406:11GlobeNewswire Inc.Second Quarter 2014 Net Sales Figures for Arzerra(r)USOTC:GNMSFGenmab A S (PK)
18/07/201408:18GlobeNewswire Inc.Genmab Announces Phase III Study of Daratumumab in Front Line Multiple MyelomaUSOTC:GNMSFGenmab A S (PK)
14/07/201408:59GlobeNewswire Inc.Genmab to Receive Milestone Payment in DuoBody Platform Collaboration with JanssenUSOTC:GNMSFGenmab A S (PK)
07/07/201409:23GlobeNewswire Inc.Genmab Reaches USD 25 Million Milestone in Daratumumab Collaboration with JanssenUSOTC:GNMSFGenmab A S (PK)
03/07/201408:38GlobeNewswire Inc.GSK and Genmab Receive EU Authorization for Arzerra(tm) (ofatumumab) as First-Line Treatment for Chronic Lymphocytic Leukemia...USOTC:GNMSFGenmab A S (PK)
27/06/201413:27GlobeNewswire Inc.GSK and Genmab announce top-line results from a Phase III study of ofatumumab versus physicians' choice for bulky fludarabine...USOTC:GNMSFGenmab A S (PK)
04/06/201401:27GlobeNewswire Inc.Genmab Announces DuoBody and HexaBody Platform Collaboration With Undisclosed Biotechnology CompanyUSOTC:GNMSFGenmab A S (PK)
30/05/201410:04GlobeNewswire Inc.Genmab Announces Ofatumumab Development Plans in RRMS and NMOUSOTC:GNMSFGenmab A S (PK)
23/05/201408:21GlobeNewswire Inc.GSK and Genmab Receive CHMP Positive Opinion for Arzerra(tm) in Combination with Chlorambucil or Bendamustine as a First-line...USOTC:GNMSFGenmab A S (PK)
19/05/201413:21GlobeNewswire Inc.GSK and Genmab Announce Topline Results from a Pivotal Head to Head Study of Ofatumumab in Combination With Chemotherapy vs R...USOTC:GNMSFGenmab A S (PK)
07/05/201410:11GlobeNewswire Inc.Genmab Announces Financial Results for the First Quarter of 2014USOTC:GNMSFGenmab A S (PK)
01/05/201414:09GlobeNewswire Inc.Genmab Announces New Phase III Study of Daratumumab in Multiple Myeloma & Improves 2014 Financial GuidanceUSOTC:GNMSFGenmab A S (PK)
30/04/201406:11GlobeNewswire Inc.First Quarter 2014 Net Sales Figures for ArzerraUSOTC:GNMSFGenmab A S (PK)
 Showing the most relevant articles for your search:USOTC:GNMSF

Su Consulta Reciente

BOV
BAUH4F
EXCELSIOR PN
BOV
BCSA34
Banco Santander
CSE
STPH
Steep Hill
LSE
SM95
Citi Fun 29
COIN
PUTETH
Profile Utility Token
COIN
TRZUST
Trazable
NASDAQ
TXMD
TherapeuticsMD
EU
H781S
H781S
BIT
S25054
SG ISSUER
BIT
P15IM9
BNP Paribas Issuance
TSXV
MQR
Monarques Gold Corporation
NYSE
XKE
Lehman Abs 7.75 Toys
AMEX
WANT
Direxion Daily Consumer ...
LSE
AG45
Citi Fun 24
USOTC
VLVOF
Volvo Car AB (PK)
LSE
VNF
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados